NCT06183983Recruiting
Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma
Source: ClinicalTrials.gov · Last updated 12 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this prospective cohort study is to assess the potential of advanced MRI for improved radiotherapy target delineation in patients diagnosed with glioblastoma. The main questions it aims to answer are: * How does the coverage of the recurrence volume by a radiotherapy plan based on advanced MRI compare to the coverage by the clinical radiotherapy plan? * How does the distribution of the dose to organs at risk by a radiotherapy plan based on advanced MRI compare to the distribution by the clinical radiotherapy plan? Participants will undergo an extended MRI-protocol prior to radiotherapy. This extended MRI-protocol includes the clinical brain tumor imaging protocol plus additional advanced MRI-sequences. Radiation treatment and patient follow-up will occur according to the clinical standard.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 53 (estimated)
- First submitted
- 12 Dec 2023
- Start date
- 3 Jan 2024
- Primary completion date
- Aug 2025
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Glioblastoma
- NCT number
- NCT06183983
What you commit to
- Study type: Interventional
- Planned participants: 53
- From 3 Jan 2024 to the primary completion date, Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiotherapy to the brain;
Other illness
- Contraindication for use of gadolinium-based contrast agent (e.g. subject having renal deficiency or known allergy);
Other
- Contraindication for (3 Tesla) MRI;
- Referred for treatment of recurrent glioblastoma;
- Unable to give informed consent
Who the study is looking for
- Written informed consent;
- Adult (18 years or older);
- Diagnosed with IDH-wildtype glioblastoma, as confirmed by pathology including molecular analysis post resection/biopsy;
- Referred to the outpatient clinic of the Dept. of Radiotherapy to undergo standard treatment with radiotherapy (30x2 Gy or 15x2.67Gy or 10x3.4Gy).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus Medical Center Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.